Evidence map›Paper›PMID 41303991›Full record

ArticleMaterials (Basel, Switzerland)2025

Application of CMT-Twin DED-Arc Process on the Fabrication of Invar 36 by In Situ Alloying.

Amaia Iturrioz, Juan Carlos Pereira, Eneko Ukar

Abstract read
In one paragraph

Article in Materials (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Amaia IturriozLORTEK Technological Centre, Basque Research and Technology Alliance (BRTA), Arranomendia Kalea 4A, 20240 Ordizia, Spain.ORCID 0000-0003-4792-1299
Juan Carlos PereiraLORTEK Technological Centre, Basque Research and Technology Alliance (BRTA), Arranomendia Kalea 4A, 20240 Ordizia, Spain.ORCID 0000-0002-4385-6197
Eneko UkarDepartment of Mechanical Engineering, University of the Basque Country (UPV/EHU), Ingeniero Torres Quevedo Plaza, 1, 48013 Bilbao, Spain.ORCID 0000-0001-9754-6154

Funding

Ministerio de Ciencia, Innovación y Universidades 00163686 / CER-20231012
6 · The paper itself

Abstract

This research explored the technical feasibility of creating a controlled chemical composition for Fe-Ni alloys using a Directed Energy Deposition (DED) arc metal additive manufacturing (AM) process in its twin wire feed mode. This method employs two independently controlled arc power sources to feed two different wires into a single torch, creating a unified melt pool protected by a single shielding gas nozzle. The research focused on producing Invar 36 (EN 1.3912), a low thermal expansion alloy, by melting and mixing steel and Ni-Fe wires using Cold Metal Transfer-Twin (CMT-Twin) technology. This method enables the fabrication of multi-material components featuring regions with distinct chemical compositions, including functional gradients, with the aim of leveraging the advantageous properties of each individual material. Furthermore, this new manufacturing route offers the possibility to avoid using some alloying elements, such as Nb, an element considered a critical raw material (CRM) in the European Union (EU). Microstructure and mechanical properties were analyzed and compared to commercial Invar 36 obtained by DED-Arc with single wire as well as the effect of the absence of Nb. Results showed that the in situ obtained alloy had 10-20% lower strength but exhibited 10-15% higher elongation compared to the commercial alloy, making it a promising alternative for advanced manufacturing by using this new manufacturing route.

Indexed as

CMT-Twin DED-Arccritical raw materialin situ alloyingInvar 36mechanical propertiesmicrostructure

Identifiers

PMID41303991
PMCPMC12654427

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.